CDK4/6 INHIBITOR
Clinical trials for CDK4/6 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new CDK4/6 INHIBITOR trials appear
Sign up with your email to follow new studies for CDK4/6 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Brand or generic? new study tests palbociclib for advanced breast cancer
Disease control OngoingThis study compares the effectiveness and safety of brand-name palbociclib (Ibrance) versus a generic version in 100 Iraqi women with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the generic works as well at controlling the disease. Parti…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: Al-Mustansiriyah University • Aim: Disease control
Last updated May 17, 2026 00:50 UTC
-
Can a simple blood test predict cancer drug side effects?
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to find genetic and blood markers that can predict which breast cancer patients will have severe side effects or poor response to a class of drugs called kinase inhibitors. Researchers will analyze DNA and blood samples from 100 women with breast cancer who are ta…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Knowledge-focused
Last updated May 13, 2026 15:58 UTC